Skip to contentC
China Pharma Holdings, Inc.
C
CPHIChina Pharma Holdings, Inc. Q3 2025 · 10-Q
Revenue$756.22K$756.22K−31.3% vs Q3 2024 Net Income-$651.48K-$651.48KN/M vs Q3 2024 EPS Diluted-$0.17-$0.17N/M vs Q3 2024 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
China Pharma Holdings, Inc. · CIK 1106644 · Engraved from SEC EDGAR
Operating Cash Flowderived-$236,987N/M Free Cash Flowderived-$237,598N/M Margins · derivedGross margin-7.9%+39.3 pt vs Q3 2024
Operating margin-83.1%+15.6 pt vs Q3 2024
Net margin-86.2%+15.5 pt vs Q3 2024
ended Sep 30, 2025 · filed Nov 12, 2025 · 43 d after period end